Neuropsychiatric involvement in systemic lupus erythematosus. Part 2: Diagnostics and therapy;Neuropsychiatrische beteiligung des systemischen lupus erythematodes. Teil 2: Diagnostik und therapie

Medizinische Klinik

Volumn 98, Issue 2, 2003, Pages 79-90

  Weiner, Stefan Markus ^a,d   Otte, Andreas ^b   Uhl, Markus ^c   Brink, Ingo ^c   Schumacher, Martin ^c   Peter, Hans Hartmut ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF FREIBURG   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Central nervous system involvement; Diagnosis; Magnetic resonance imaging; Positron emission tomography; Single photon emission computed tomography; SLE, neuropsychiatric; Systemic lupus erythematosus; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CORTICOSTEROID; COUMARIN; COUMARIN ANTICOAGULANT; CREATINE; CYCLOPHOSPHAMIDE; CYSTEINE ETHYL ESTER TC 99M; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GLUCOSE; HALOPERIDOL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; LACTIC ACID; METHYLPREDNISOLONE; N ACETYLASPARTIC ACID; OXYGEN 15; PHOSPHOLIPID ANTIBODY; PREDNISONE; WATER O 15;

ANGIOGRAPHY; ANTICOAGULATION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID EXAMINATION; CLINICAL FEATURE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELECTROENCEPHALOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; REVIEW; RISK FACTOR; SEROLOGY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOSIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; COUMARINS; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PLASMAPHERESIS; PRIMARY PREVENTION; THROMBOSIS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0345701450     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-003-1230-8     Document Type: Review

References (116)

1. Abel T, Gladman DD, Urowitz MB. Neuropsychiatric lupus. J Rheumatol 1980;7:325-33.
2. Ahmed F, Aziz T, Kaufman LD. Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus. J Rheumatol 1999;26:1609-12.
3. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999;42:1785-96.
4. Asherson RA, Cervera K, Piette JC, Font J, Lie JT, Burcoglu A, Lim K, Munoz-Rodriguez FJ, Levy RA, Boue F, Rossert J, Ingelmo M. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998;77:195-207.
5. Asherson RA, Khamashta MA, Gil A, Vazquez JJ, Chan O, Baguley E, Hughes GR. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med 1989; 86:391-9.
6. Baca V, Lavalle C, Garcia R, Catalan T, Sauceda JM, Sanchez G, Martinez I, Ramirez ML, Marquez LM, Rojas JC. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999;26:432-9.
7. Barile L, Lavalle C. Transverse myelitis in systemic lupus erythematosus-the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol 1992;19:370-2.
8. Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J [Clin Res] 1983;287:1021-3.
9. Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987;317:265-71.
10. Boumpas DT, Scott DE, Balow JE. Neuropsychiatric lupus: a case for guarded optimism. J Rheumatol 1993;20:1641-3.
11. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991; 81:975-84.
12. Brooks WM, Jung RE, Ford CC, Greinel EJ, Sibbitt WL Jr. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1999;26:81-5.
13. Brooks WM, Sabet A, Sibbitt WL Jr, Barker PB, van Zijl PC, Duyn JH, Moonen CT. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J Rheumatol 1997;24:2323-9.
14. Bruyn GA. Controversies in lupus: nervous system involvement. Ann Rheum Dis 1995;54:159-67.
15. Carbotte RM, Denburg SD, Denburg JA, Nahmias C, Garnett ES. Fluctuating cognitive abnormalities and cerebral glucose metabolism in neuropsychiatric systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1992;55:1054-9.
16. Chinn RJ, Wilkinson ID, Hall-Craggs MA, Paley MN, Shortall E, Carter, S, Kendall BE, Isenberg DA, Newman SP, Harrison MJ. Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:36-46.
17. Christenson RH, Behlmer P, Howard JF Jr, Winfield JB, Silverman LM. Interpretation of cerebrospinal fluid protein assays in various neurologic diseases. Clin Chem 1983;29:1028-30.
18. Colamussi P, Giganti M, Cittanti C, Dovigo L, Trotta F, Tola MR, Tamarozzi R, Lucignani G, Piffanelli A. Brain single-photon emission tomography with 99mTc-HMPAO in neuropsychiatric systemic lupus erythematosus: relations with EEG and MRI findings and clinical manifestations. Eur J Nucl Med 1995;22:17-24.
19. Colamussi P, Trotta F, Ricci R, Cittanti C, Govoni M, Barbarella G, Giganti M, Bajocchi G, Uccelli L, Trevisan C, Piffanelli A. Brain perfusion SPET and proton magnetic resonance spectroscopy in the evaluation of two systemic lupus erythematosus patients with mild neuropsychiatric manifestations. Nucl Med Commun 1997;18:269-73.
20. Csepany T, Gulyas B, Tron L, Szakall S, Kiss E, Kollar J, Sikula J, Szegedi G, Csiba L. Cerebral positron emission tomographic study in systemic lupus erythematosus. Orv Hetil 1997;138:1947-52.
21. De Jong BM, Pruim J, Sinnige LG, Beintema KD, Spronk PE, Bootsma H, Kallenberg CG, van Zomeren AH, Haaxma-Reiche H. Regional specific changes of cerebral metabolism in systemic lupus erythematosus identified by positron emission tomography. Eur Neurol 1999;41:187-93.
22. Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:1311-20.
23. Derksen RH, Bouma BN, Kater L. The association between the lupus anticoagulant and cerebral infarction in systemic lupus erythematosus. Scand J Rheumatol 1986;15:179-84.
24. Derksen RH, De Groot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993;52:689-92.
25. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasctilitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988;23:380-4.
26. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol 2000;57:1422-7.
27. Falcini F, De Cristofaro MT, Ermini M, Guarnieri M, Massai G, Olmastroni M, Masi A, Pupi A, Meldolesi U. Regional cerebral blood flow in juvenile systemic lupus erythematosus: a prospective SPECT study. Single photon emission computed tomography. J Rheumatol 1998;25:583-8.
28. Fazekas F, Alavi A, Chawluk JB, Zimmerman RA, Hackney D, Bilaniuk L, Rosen M, Alves WM, Hurtig HI, Jamieson DG. Comparison of CT, MR, and PET in Alzheimer's dementia and normal aging. J Nucl Med 1989;30:1607-15.
29. Fierro B, Brighina F, Amico L, Aloisio A, Buffa D, Caravaglios G, La BV, Manfre L, Oliveri M, Daniele O. Evoked potential study and radiological findings in patients with systemic lupus erythematosus. Electromyogr Clin Neurophysiol 1999;39:305-13.
30. Forastiero RR, Martinuzzo ME, Kordich LC, Carreras LO. Reactivity to beta 2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996;75:717-20.
31. Fox DA, McCune WJ. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994;20:265-99.
32. Futrell N, Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 1989;20:583-91.
33. George MS, Ketter TA, Post RM. SPECT and PET imaging in mood disorders. J Clin Psychiatry 1993; 54:Suppl:6-13.
34. Glanz BI, Schur PH, Khoshbin S. EEG abnormalities in systemic lupus erythematosus. Clin Electroencephalogr 1998;29:128-31.
35. Gonzalez-Crespo MR, Blanco FJ, Ramos A, Ciruelo E, Mateo I, Lopez Pino MA, Gomez-Reino JJ. Magnetic resonance imaging of the brain in systemic lupus erythematosus. Br J Rheumatol. 1995;34:1055-60.
36. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999;354:1031.
37. Griffey RH, Brown MS, Bankhurst AD, Sibbitt RR, Sibbitt WL Jr. Depletion of high-energy phosphates in the central nervous system of patients with systemic lupus erythematosus, as determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Arthritis Rheum 1990;33:827-33.
38. Grunwald F, Schomburg A, Badali A, Ruhlmann J, Pavics L, Biersack HJ. 18FDG PET and acetazolamide-enhanced 99mTc-HMPAO SPET in systemic lupus erythematosus. Eur J Nucl Med 1995; 22:1073-7.
39. Guidelines on oral anticoagulation, 3rd edn. Br J Haematol 1998;101:374-87.
40. Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999;42:728-34.
41. Hanly JG, Walsh NM, Fisk JD, Eastwood B, Hong C, Sherwood G, Jones JV, Jones E, Elkon K. Cognitive impairment and autoantibodies in systemic lupus erythematosus. Br J Rheumatol 1993;32:291-6.
42. Harisdangkul V, Doorenbos D, Subramony SH. Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. J Neurol 1995;242:326-31.
43. Henneberg A, Mayle DM, Kornhuber HH. Antibodies to brain tissue in sera of patients with chronic progressive multiple sclerosis. J Neuroimmunol 1991;34:223-7.
44. Higashi K, Nishikawa T, Seki H, Oguchi M, Nambu Y, Ueda Y, Yuasa K, Tonami H, Okimura T, Yamamoto I. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med 1998;39:9-15.
45. Ishikawa O, Ohnishi K, Miyachi Y, Ishizaka H. Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging. Relationship to anticardiolipin antibody. J Rheumatol 1994;21:87-90.
46. Isshi K, Hirohata S. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1996;39:1483-90.
47. Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 1998;41:1819-27.
48. Jarek MJ, West SG, Baker MR, Rak KM. Magnetic resonance imaging in systemic lupus erythematosus patients without a history of neuropsychiatric lupus erythematosus. Arthritis Rheum 1994;37:1609-13.
49. Joffe RT, Denicoff KD, Rubinow DR, Tsokos G, Balow JE, Pillemer SE. Mood effects of alternate-day corticosteroid therapy in patients with systemic lupus erythematosus. Gen Hosp Psychiatry 1988;10:56-60.
50. Kao CH, Ho YJ, Lan JL, ChangLai SP, Liao KK, Chieng PU. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Arthritis Rheum 1999;42:61-8.
51. Kao CH, Lan JL, ChangLai SP, Liao KK, Yen RF, Chieng PU. The role of FDG-PET, HMPAO-SPET and MRI in the detection of brain involvement in patients with systemic lupus erythematosus. Eur J Nucl Med 1999;26:129-34.
52. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
53. Kodama K, Okada S, Hino T, Takabayashi K, Nawata Y, Uchida Y, Yamanouchi N, Komatsu N, Ikeda T, Shinoda N, Murakami A, Sakamoto T, Sato T. Single photon emission computed tomography in systemic lupus erythematosus with psychiatric symptoms. J Neurol Neurosurg Psychiatry 1995;58:307-11.
54. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000;59:120-4.
55. Kovacs JA, Urowitz MB, Gladman DD, Zeman R. The use of single photon emission computerized tomography in neuropsychiatric SLE: a pilot study. J Rheumatol 1995;22:1247-53.
56. Kozora E, West SG, Kotzin BL, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1998;41:41-7.
57. Kuwabara Y, Ichiya Y, Otsuka M, Tahara T, Fukumura T, Gunasekera R, Masuda K. Differential diagnosis of bilateral parietal abnormalities in 1-123 IMP SPECT imaging. Clin Nucl Med 1990;15:893-9.
58. Lewis SW, Ford RA, Syed GM, Reveley AM, Toone BK. A controlled study of 99mTc-HMPAO single-photon emission imaging in chronic schizophrenia. Psychol Med 1992;22:27-35.
59. Liem MD, Gzesh DJ, Flanders AE. MRI and angiographic diagnosis of lupus cerebral vasculitis. Neuroradiology 1996;38:134-6.
60. Lin WY, Wang SJ, Yen TC, Lan JL. Technetium-99m-HMPAO brain SPECT in systemic lupus erythematosus with CNS involvement. J Nucl Med 1997;38:1112-5.
61. Ling MH, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy. Psychiatric aspects. Arch Gen Psychiatry 1981;38:471-7.
62. Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder E, Gur RE. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med 1995;36:1141-9.
63. Manzi S. Systemic lupus erythematosus: a model for atherogenesis? Rheumatology 2000;39:353-9.
64. Matsukawa Y, Nishinarita S, Hayama T, Sawada S, Horie T. Clinical significance of electroencephalograph in patients with systemic lupus erythematosus. Ryumachi 1993;33:20-8.
65. McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet's disease involving the nervous system. J Neurol Neurosurg Psychiatry 1995;58:548-54.
66. McVerry BA, Spearing R, Smith A. SLE anticoagulant: transient inhibition by high dose immunoglobulin infusions. Br J Haematol 1985;61:579-80.
67. Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999;42:735-41.
68. Meusser S, Rubbert A, Manger B, Bock E, Platsch G, Feistel H, Engelhardt A, Wolf F, Kalden JR. 99m-Tc-HMPAO-SPECT in diagnosis of early cerebral vasculitis. Rheumatol Int 1996;16:37-42.
69. Miller DH, Buchanan N, Barker G, Morrissey SP, Kendall BE, Rudge P, Khamashta M, Hughes GR, McDonald WI. Gadolinium-enhanced magnetic resonance imaging of the central nervous system in systemic lupus erythematosus. J Neurol 1992;239:460-4.
70. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41.
71. Otte A. Das Halswirbeläulen-Schleudertrauma: neue Wege der funktionellen Bildgebung des Gehims - ein Ratgeber für Ärzte und Betroffene. Berlin-Heidelberg-New York-Tokyo: Springer, 2001.
72. Otte A, Ettlin TM, Nitzsche EU, Wachter K, Hoegerle S, Simon GH, Fierz L, Moser E, Mueller-Brand J. PET and SPECT in whiplash syndrome: a new approach to a forgotten brain? J Neurol Neurosurg Psychiatry 1997;63:368-72.
73. Otte A, Weiner SM, Hoegerle S, Wolf R, Juengling FD, Peter HH, Nitzsche EU. Neuropsychiatric systemic lupus erythematosus before and after immunosuppressive treatment: a FDG PET study. Lupus 1998;7:57-9.
74. Otte A, Weiner SM, Peter HH, Mueller-Brand J, Goetze M, Moser E, Gutfleisch J, Hoegerle S, Juengling FD, Nitzsche EU. Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study. Eur J Nucl Med 1997;24:787-91.
75. Perani D, Di P V, Vallar G, Cappa S, Messa C, Bottini G, Berti A, Passafiume D, Scarlato G, Gerundini P. Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease. J Nucl Med 1988;29:1507-14.
76. Perry PJ, Tsuang MT, Hwang MH. Prednisolone psychosis: clinical observations. Drug Intell Clin Pharm 1984;18:603-9.
77. Pozzilli C, Passafiume D, Bernardi S, Pantano P, Incoccia C, Bastianello S, Bozzao L, Lenzi GL, Fieschi C. SPECT, MRI and cognitive functions in multiple sclerosis. J Neurol Neurosurg Psychiatry 1991; 54:110-5.
78. Primavera A, Audenino D, Mavilio N, Cocito L. Reversible posterior leucoencephalopathy syndrome in systemic lupus and vasculitis. Ann Rheum Dis 2001;60:534-7.
79. Provenzale JM, Barboriak DP, Allen NB, Ortel TL. Patients with antiphospholipid antibodies: CT and MR findings of the brain. AJR Am J Roentgenol 1996;167:1573-8.
80. Provenzale JM, Barboriak DP, Allen NB, Ortel TL. Antiphospholipid antibodies: findings at arteriography. AJNR Am J Neuroradiol 1998;19:611-6.
81. Provenzale JM, Barboriak DP, Gaensler EH, Robertson RL, Mercer B. Lupus-related myelitis: serial MR findings. AJNR Am J Neuroradiol 1994;15:1911-7.
82. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999;26:325-30.
83. Reiff A, Miller J, Shaham B, Bernstein B, Szer IS. Childhood central nervous system lupus; longitudinal assessment using single photon emission computed tomography. J Rheumatol 1997;24:2461-5.
84. Ritchlin CT, Chabot RJ, Alper K, Buyon J, Belmont HM, Roubey R, Abramson SB. Quantitative electroencephalography. A new approach to the diagnosis of cerebral dysfunction in systemic lupus erythematosus. Arthritis Rheum 1992;35:1330-42.
85. Rodriguez G, Nobili F, De Carli F, Francione S, Marenco S, Celestino MA, Hassan K, Rosadini G. Regional cerebral blood flow in chronic stroke patients. Stroke 1993;24:94-9.
86. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
87. Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to beta 2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum 1996;39:1606-7.
88. Rovaris M, Filippi M. The value of new magnetic resonance techniques in multiple sclerosis. Curr Opin Neurol 2000;13:249-54.
89. Rubbert A, Marienhagen J, Pimer K, Manger B, Grebmeier J, Engelhardt A, Wolf F, Kalden JR. Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum 1993;36:1253-62.
90. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus. Lancet 2001;357:1027-32.
91. Sabbadini MG, Manfredi AA, Bozzolo E, Ferrario L, Rugarli C, Scorza R, Origgi L, Vanoli M, Gambini O, Vanzulli L, Croce, D, Campana A, Messa C, Fazio F, Tincani A, Anzola G, Cattaneo R, Padovani A, Gasparotti R, Gerli R, Quartesan R, Piccirilli M, Farsi A, Emmi E, Passaleva A. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus 1999;8:11-9.
92. Sabet A, Sibbitt WL Jr, Stidley CA, Danska J, Brooks WM. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 1998; 29:2254-60.
93. Sailer M, Burchert W, Ehrenheim C, Smid HG, Haas J, Wildhagen K, Wurster U, Deicher H. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 1997;244:186-93.
94. Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, Kotzin BL. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991;90:54-62.
95. Sibbitt WL Jr, Brooks WM, Haseler LJ, Griffey RH, Frank LM, Hart BL, Sibbitt RR. Spin-spin relaxation of brain tissues in systemic lupus erythematosus: A method for increasing the sensitivity of magnetic resonance imaging for neuropsychiatric lupus. Arthritis Rheum 1995;38:810-8.
96. Sibbitt WL Jr, Haseler LJ, Griffey RH, Hart BL, Sibbitt RR, Matwiyoff NA. Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. AJNR Am J Neuroradiol 1994;15:923-8.
97. Sibbitt WL Jr, Sibbitt RR, Brooks WM. Neuroimagingin neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999;42:2026-38.
98. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992;19:47-52.
99. Stefan H, Kuhnen C, Biersack HJ, Reichmann K. Initial experience with 99m Tc-hexamethylpropylene amine oxime (HM-PAO) single photon emission computed tomography (SPECT) in patients with focal epilepsy. Epilepsy Res 1987;1:134-8.
100. Stimmler MM, Coletti PM, Quismorio FP Jr. Magnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 1993;22:335-49.
101. Stoppe G, Wildhagen K, Seidel JW, Meyer GJ, Schober O, Heintz P, Kunkel H, Deicher H, Hundeshagen H. Positron emission tomography in neuropsychiatric lupus erythematosus. Neurology 1990;40:304-8.
102. Stratta P, Canavese C, Ferrero S, Grill A, Schinco PC, Montaruli B. Failure of the war to the knife against antiphospholipid antibodies by conventional immunosuppressive therapy in systemic lupus erythematosus. Clin Nephrol 1996; 46:356.
103. Teh L-S, Isenberg DA. Antiribosomal P protein antibodies in systemic lupus erythematosus. Arthritis Rheum 1994;37:307-15.
104. Trysberg E, Lindgren I, Tarkowski A. Autologous stem cell transplantation in a case of treatment resistant central nervous system lupus. Ann Rheum Dis 2000;59:236-8.
105. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, Koike T. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466-74.
106. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus [Review]. Rheumatology (Oxf) 2000; 39:238-44.
107. Vermylen J, Blockmans D, Spitz B, Deckmyn H. Thrombosis and immune disorders. Clin Haematol 1986;15:393-412.
108. Wallace DJ. Plasmapheresis in lupus. Lupus 1993;2:141-3.
109. Weiner SM, Otte A, Schumacher M, Brink I, Juengling FD, Sobanksi T, Nitzsche EU, Peter HH. Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesions in neuropsychiatric systemic lupus erythematosus. Lupus 2000;9:386-9.
110. Weiner SM, Otte A, Schumacher M, Klein R, Gutfleisch J, Brink I, Otto P, Nitzsche EU, Moser E, Peter HH. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 2000;59:377-85.
111. West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995;99:153-63.
112. Winder A, Molad Y, Ostfeld I, Kenet G, Pinkhas J, Sidi Y. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 1993;20:495-8.
113. Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HA 3, Koffler D. Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med 1983;74:837-44.
114. Woods RP, Iacoboni M, Mazziotta JC, Brief report. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994;331:1689-92.
115. Yoshio T, Masuyama J, Ikeda M, Tamai K, Hachiya T, Emori T, Mimori A, Takeda A, Minota S, Kano S. Quantification of antiribosomal PO protein antibodies by ELISA with recombinant PO fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J Rheumatol 1995;22:1681-7.
116. Zimmerman RD, Fleming CA, Lee BC, Saint-Louis LA, Deck MD. Periventricular hyperintensity as seen by magnetic resonance: prevalence and significance. AJR Am J Roentgenol 1986; 146:443-50.